The 2017 Muscle Study Group Scientific Annual Meeting

"Neuromuscular Therapeutics: Bench to Bedside and Beyond"

September 23-25, 2017

Snowbird Summer and Ski Resort in Snowbird , Utah

		Day 1: Saturday, September 23, 2017		
Гime	Session	Title Topic	Faculty	Room
7:00-8:00 am	Breakfast			Golden Cliff
':30-8:00 am	Check-In			Ballroom Lobb
3:00- 12:00 am	Investigator Meetings:	Closed to Public		
8:00-9:00 a		FSHD Clinical Trials Research Network	Jeffrey Statland	Manuin A
8:00-9:00 a	ım	PCORI	Richard Barohn	Magpie A Magpie B
9:00-10:00 a	m	NIH sIBM Nautral History Study	Tahseen Mozaffar	Magpie A
J.00-10.00 6		Memantine Memantine	Richard Barohn	Magpie B
10:00-11:00 a	ım	IPANEMA	Tahseen Mozaffar	Magpie A
		IBM International Genetics Consortium		
10:00-10:30 a	m	Study	Pedro Machado and Michael Benatar	Magpie B
10:30-11:00 a		MGSCIg	Mazen Diamchkie	Magpie B
11:00-12:00a		Arimoclomol in IBM	Mazen Dimachkie	Magpie A
11:00-12:00a		FOR-DMD	Robert Griggs	Magpie B
l2:00-1:30 pm	Lunch	Advanta Charle Consum Franchism Consumition	- Air -	
		Muscle Study Group Executive Committee Mee	eting	Magpie A
1:30-5:00 pm	Young Investigator, Coordinator, Clinical Evaluator	and Underrepresented NM Minority Workshop		Ballroom
	Invited Speakers:			
	•	Advice to Young Investigators	Richard Barohn, MD	
1:30-2:00 p	m	Advice to Young investigators	University of Kansas Medical Center	
		NIH funding	Glen Nuckolls, PhD	
2:00-2:15 p	m	NIA Junuing	National Institute of Health	
		MDA Support Programs	Grace Pavlath, PhD	
2:15-2:30 p	m	WEA Support Fograms	Muscular Dystrophy Association	
2:30-3:30 p	m Panel Discussion:			
		Early Career Development: How to Get Start Mod		
		Moderators		
		Jeffrey Statland,	Jaya Trivedi,	
		University of Kansas Medical Center	UT Southwestern Medical Center	
		Panel Members		
		Kevin Flanigan,	Gordon Smith, MD	
		Nationwide Childrens Hospital	University of Utah Health Care	
		Lindsay Alfano,	Richard Barohn, MD	
		Nationwide Childrens Hospital	University of Kansas Medical Center	
		Carlayne Jackson, UT Health San Antonio	Laura Herbelin	
		OT HEAITH SUN ANTONIO	University of Kansas Medical Center	
3:30-3:50p	m Break			Ballroom Lobb
2.E0 E.00 =	m Break Out Discussion:			
3.30-3.00 μ		e on the panel and 2017 planning committee members	s	
5:00-6:00pm	10 Minute Update of MSG Studies	paner and 2027 planning committee member.		Ballroom
6:00-7:30 pm	Dinner			Golden Cliff
7:30 PM	Robert C. Griggs Annual MSG Keynote Speaker			Ballroom
		Gene Therapy Development	Brian Kasper, PhD Nationwide Childrens Hospital	
		., .	Nationwide Childrens Hospital	Golden Cliff &
				Joiden Cilli &

The 2017 Muscle Study Group Scientific Annual Meeting

"Neuromuscular Therapeutics: Bench to Bedside and Beyond"
September 23-25, 2017

Snowbird Summer and Ski Resort in Snowbird , Utah

	Day 2: S	Sunday, September 24, 2017		
Time	Session		Faculty	Room
7:00-8:00 am 7:00-8:00 am	Breakfast Poster Set-Up			Golden Cliff Primrose
8:00-8:30 am	Welcome and State of the Muscle Study Group Address		Richard Barohn and Michael Hanna	Ballroom
3:30-10:10 am	Session I: Platforms for Developments of Novel Therapeutic	cs Moderator	TBD	Ballroom
8:30-8:55 am		Cas9	Rhonda Bassel-Duby, PhD UT Southwestern	
9:00-9:25 am		Developed Processed Around High Throughput Screening	Chris Gibson, MD, PhD Recursion Pharma	
9:30-9:55 am		ALS Therapeutics	Robert Baloh, MD, PhD Cedars- Sinai	
10:00-10:25 am		Dup2 Mouse to Therapy	Kevin Flannigan, MD Nationwide Childrens Hospital	
0:30-11:00 am	Break			Ballroom Lobby
1:00-1:00 pm	Session II: Data Mining in Neuromuscular Therapeutics	Moderator	TBD	Ballroom
11:00-11:45 am		Natural History and MRI Outcome Measures in Global Multi-Center Dysferlinopathy Studies	Jordi Diaz, MD Hospital de la Santa Creu i Sant Pau	
11:50-12:15 am		Dysferlin Gene Therapy	Louise Rodino-Klapac, PhD Nationwide Children's Hospital	
12:20-12:45 pm		ALS Natural History Study	Matt Harms, MD Columbia University	
42.50.4.45		Overview of the MDStar New Project	Paul Romitti, PhD University of Iowa College of Public	
12:50-1:15 pm			Health	Calala a Cliff
1:20-3:00 pm	Lunch & Networking			Golden Cliff
:00-3:50 pm	Platform Presentation: Session I	Moderator	TBD	Ballroom
2:00-2:10 pm		Outcome Measures in Limb Girdle Muscualr Dystrophy	Jennifer Mansour Kennedy Kreiger Institute	
2:10-2:20 pm		ITGA7 Mutations Cause Arrhythmia and Respiratory Muscle Weakness Subcutaneous immunoglobulin for	Enrico Bugiardini University College London	
		Maintenance Treatment in CIDP - A multi- Center, randomized, Double Blind Trail:	Mazen Dimachkie, MD University of Kansas Medical Center	
2:20-2:30 pm		The PATH Study Human motor Neurospheres Reveal Altered Neurofilament Distribution in	Mario Saporta, MD	
2:30-2:40 pm		CMT2E Neuro Axons Thromboembolic Risk in Inflammatory	University of Miami Health System Aisling Carr, PhD	
2:40-2:50 pm		Neuromuscular Disease Patients on Long- Term IVIg	National Hospital for Neurology and Neurosurgery	
:00-5:55 pm	Session III: Outcome Measures in Neuromuscular Disease	Moderator	TBD	Ballroom
3:00-3:25 pm		Image DMD	TBD Lindsay Alfano, PT	
3:30-3:55 pm		Novel functional Outcome Measures	Nationwide Childrens Hospital Chad Heatwole, MD	
4:00-4:25 pm		PROs MRI Biomarker Outcome Measures in	University of Rochester Medical Center John Thornton, PhD	
4:30-4:55 pm		Neuromuscular Diseases	University of College London, UK	
5:00-7:00 pm	Dinner			Golden Cliff
7:00-10:00	Walk Through Poster Session & Evening Reception			Primrose & Atriu Patio

The 2017 Muscle Study Group Scientific Annual Meeting

"Neuromuscular Therapeutics: Bench to Bedside and Beyond"

September 23-25, 2017

Snowbird Summer and Ski Resort in Snowbird , Utah

	Day	3: Monday, September 25, 2017		
ime	Session	Faculty		
00-8:00 am	Breakfast	2017-2018 MSG Planning Committee Meetin	g	Golden Cliff Magpie B
00-8:50 am	Platform Presentation: Session II	Moderator	TBD	Ballroom
8:00-8:10 ar	n	Nusinersen for SMA1: The Italian Expanded Access Program (EAP) Experience	Valeria Sansone, MD University of Milan	
8:10-8:20 ar	n	Clinical, Pathological, and Radiological Correlates in FSHD Patients: Update from the Seattle Wellstone Project	Leo Wang, MD, PhD University of Washington Medicine	
8:20-8:30 ar	m	A Phenotypic Profile of Cognitive function in CMD	Melissa Dixon, PhD University of Utah Health	
8:30-8:40 an	n	Tongue Abnormalities on Brain MRI in Patients with Neuromusucular Disoerders	Chafic Karam, MD Oregon Health Science University	
8:40-8:50 an	n	RCT of Bumetanide in Hypokalaemic Periodic Paralysis	Renata Scalco, PhD University College London	
00-11:00 am	Session IV: Post Marketing Surveillance in Neuromuscul	ar Disease Moderator	TBD	Ballroom
9:00-9:25 ar	n	From the MDX Mouse to an Approved Therapy	Edward Kaye, MD Sarepta Therapeutics	
9:30-9:55 ar	m	Biogen (SMA)	Sandy Reyna, MD Biogen	
10:00-10:25 ar	n	NeoGAA Trial	Susan Sparks, MD, PhD Genzyme	
10:30-10:55 an		Health Economics in Rare NM Diseases- Points to Consider	Gorana Capkun-Niggli, PhD Novartis Pharmaceuticals	
1:00-12:30 pm	Lunch			Golden Cliff
2:30-2:00pm	Session V: Identification of Neuromuscular Disease	Moderator	TBD	Ballroom
12:30-12:55 pr	n	Newborn Screening in DMD	Jennifer Kwon, MD University of Rochester Medical Center	
1:00-1:25 pr	n	Presymptomatic Diagnosis and Therapy in SMA	Eduardo Tizzano MD, PhD, Hospital Valle Hebronm Barcelona, Spain	
1:30-1:55 pr		Genetic Testing in LGMD	Matt Wicklund, MD Penn State Health	